Novo Nordisk posted solid quarterly results Wednesday before the market open.Sales came in at 71.3 billion Danish crowns ($10 ...

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

Novo Nordisk A/S’s sales of blockbuster weight-loss drug Wegovy beat expectations in the third quarter, a potential relief ...

Oculus VR founder Palmer Luckey Palmer Luckey — who founded defense tech company Anduril and the VR company Oculus ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...

The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from Fullerton Wellness had an unidentified "black particulate" floating in it.

The Danish drugmaker plans to introduce a combination drug, CagriSema, that could result in 25% weight loss — higher than ...

Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are ...

The study was funded by Novo Nordisk. Kahn serves as an advisory panel member/consultant for Abarceo Pharma, Amgen, AltPep, Anji, Biomea Fusion, Eli Lilly and Company, Merck, Neurimmune, Novo Nordisk, ...